← All compounds
Emerging Research

DSIP

Delta Sleep-Inducing Peptide | Sleep & Stress Modulator

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) discovered in 1974 in rabbit brain. Originally isolated for its sleep-promoting properties, DSIP has since been found to have diverse neuromodulatory effects including stress reduction, pain modulation, and endocrine regulation, though its exact mechanisms and clinical efficacy remain subjects of ongoing research.

Daily dose

100-300mcg

Frequency

1x daily

Cycle length

5-10 days

Storage

2-8°C

Key benefits

Enhanced sleep quality through slow-wave sleep promotion, stress reduction via cortisol modulation, potential pain relief, and mood stabilization without traditional sedative effects.

How it works

Modulates multiple neurotransmitter systems including GABA enhancement, NMDA receptor interaction, and endogenous opioid system modulation. Also regulates hypothalamic-pituitary-adrenal axis.

Dosage protocols

Goal

Sleep Enhancement

Dose

100-200mcg · Once nightly

Route

Subcutaneous

Goal

Chronic Pain

Dose

250-300mcg · Daily

Route

IV or SubQ

Goal

Stress Management

Dose

150mcg · Evening

Route

Subcutaneous

Goal

Withdrawal Support

Dose

200-300mcg · Twice daily

Route

IV preferred

Goal

Athletic Recovery

Dose

100-150mcg · Post-training

Route

Subcutaneous

Research indications

sleep

Deep Sleep Enhancement — Promotes delta wave sleep, the most restorative sleep phase for physical recovery
Sleep Efficiency — Reduces sleep latency and nocturnal awakenings without morning grogginess
Natural Sleep Architecture — Supports natural sleep cycles rather than forcing sedation like traditional sleep aids

mood

Stress Response Modulation — Regulates cortisol and ACTH release, buffering against chronic stress
Mood Stabilization — Increases serotonin and endorphin production for improved emotional balance
Anxiety Reduction — Calms overactive stress pathways without sedative side effects

metabolic

Pain Modulation — Analgesic effects through endogenous opioid system interaction
Hormonal Balance — Influences growth hormone, LH, and other endocrine functions
Withdrawal Support — Clinical use in alcohol and opioid withdrawal symptom management

Administration

injectable
nasal

Interactions

Synergistic
Melatonin — Both regulate sleep-wake cycles - DSIP enhances slow-wave sleep while melatonin regulates circadian rhythm, creating complementary sleep benefits
Monitor Combination
GABA Agonists — DSIP enhances GABA activity - monitor for excessive sedation when combining with benzodiazepines or other GABA modulators
Compatible
Cortisol Modulators — DSIP helps regulate cortisol - can be used alongside adaptogenic compounds for comprehensive stress management
Synergistic
Selank — Complementary anxiolytic effects - Selank reduces anxiety while DSIP improves sleep and stress response
Compatible
Semax — Different mechanisms - Semax for daytime cognition, DSIP for nighttime recovery, creating 24-hour optimization
Use Caution
Opioid Medications — DSIP may modulate opioid receptors and has been used in withdrawal - professional supervision required with opioid medications
Compatible
Growth Hormone Peptides — No direct interaction - DSIP may support natural GH release during sleep without interfering with GH peptides
Synergistic
Epitalon — Both support circadian regulation - Epitalon enhances melatonin production while DSIP improves sleep quality

Safety notes

Generally well-tolerated with minimal side effects

Some users report mild drowsiness or dizziness initially

Occasional reports of headaches in sensitive individuals

No tolerance or dependence reported in studies

Avoid driving until effects are known

Not recommended during pregnancy or breastfeeding

Research studies

Stroke Recovery in Rats (2021)

Rats | 120 μg/kg nasal | 7 days | Enhanced motor recovery

Intranasal DSIP administration before and after induced stroke accelerated motor function recovery without significantly reducing infarct size, suggesting neuroprotective mechanisms.

Chronic Insomnia Double-Blind Study (1991)

Human | 15-30 nmol | 6 consecutive nights | Improved sleep efficiency

Double-blind crossover study showed DSIP improved objective sleep quality with higher sleep efficiency and shorter sleep latency compared to placebo, though subjective improvements were modest.

Endocrine Modulation Research (1988)

Human/Animal | Various doses | Multiple studies | Hormone regulation

Multiple studies demonstrated DSIP modulates ACTH, cortisol, and growth hormone release, suggesting broad neuroendocrine regulatory effects beyond sleep.

Chronic Pain Pilot Study (1984)

Human | 25 nmol IV | 10 days | 6/7 patients improved

DSIP significantly reduced pain levels in 6 of 7 patients with chronic pain conditions including migraine and tinnitus, with simultaneous reduction in accompanying depression.

Alcohol and Opioid Withdrawal (1984)

Human | Variable doses | 5-10 days | Symptom reduction

Clinical reports showed DSIP administration helped manage withdrawal symptoms in both alcohol and opioid-dependent patients, improving sleep and reducing anxiety.

Sleep Pressure Induction Study (1983)

Human | 25 nmol/kg IV | Single dose | 59% sleep increase

Subjects reported immediate sleep pressure sensation with 59% increase in total sleep time within 130 minutes, plus improved subsequent night sleep efficiency.

Related compounds

SelankPE-22-28 (Mini-Spadin)VIPOxytocin